Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.


To the Editor: Ruzicka et al. (March 2 issue)1 report encouraging findings of a phase 2, randomized, double-blind, placebo-controlled clinical trial that evaluated the effects of the interleukin-31 antagonist nemolizumab in patients with moderate-to-severe atopic dermatitis. The primary outcome of the trial was the percentage change in the score on a… (More)
DOI: 10.1056/NEJMc1704013


Cite this paper

@article{Egeberg2017AntiInterleukin31RA, title={Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.}, author={Alexander Egeberg and Jacob Pontoppidan Thyssen and Jashin J. Wu}, journal={The New England journal of medicine}, year={2017}, volume={376 21}, pages={2093} }